About
Scynexis Inc (NASDAQ:SCYX) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 31 2026
SCYNEXIS Announces $40.0 Million Private Placement
Mar 31 2026
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Mar 31 2026
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
Mar 4 2026
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
Feb 26 2026
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
Financials
Revenue
$20.6 M
Market Cap
$39.66 M
EPS
-0.17
Translate